The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Bristol Myers Squibb's Krazati, in combination with cetuximab, failed to significantly improve survival rates in metastatic colorectal cancer patients compared to chemotherapy. Meanwhile, the European Medicines Agency has initiated a rolling review of Revolution Medicines' experimental treatment for pancreatic cancer. Additionally, HitGen announced that its partner BioAge Labs has commenced a Phase 2 clinical trial for BGE-102, an oral inhibitor targeting cardiovascular risk.